Rapid high-performance liquid chromatographic measurement of buspirone in human plasma after overdose

Biomedical Chromatography

Volumn 18, Issue 9, 2004, Pages 637-640

  Péhourcq, Fabienne ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Anxiolytic drug; Buspirone; HPLC; Overdosage

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PLASMA (HUMAN); PLASMA STABILITY;

ANXIOLYTIC DRUG; BUSPIRONE; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; HPLC; HUMAN PLASMAS; LIQUID-LIQUIDS; MEASUREMENTS OF; OVERDOSAGE; PERFORMANCE; REVERSED-PHASE HIGH PERFORMANCE;

QUALITY CONTROL;

BUSPIRONE; QUINUPRISTIN;

ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; CHEMICAL PROCEDURES; CONCENTRATION (PARAMETERS); CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG OVERDOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; QUALITY CONTROL; STANDARD; THERMOSTABILITY; ULTRAVIOLET RADIATION;

EID: 9944234955     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.366     Document Type: Article

References (13)

1. Ary K, Rona K, Ondi S and Gachàlyi B. High-performance liquid chromatographic method with coulometric detection for the determination of buspirone in human plasma by means of a column-switching technique. Journal of Chromatography A 1998; 797: 221.
2. Baselt RC and Cravey RH. Disposition of Toxic Drugs and Chemical in Man. Chemical Toxicology Institute: Foster City, CA, 1995; 96.
3. Catalino G, Catalino MC and Hanley PF. Seizures associated with buspirone overdose: case report and literature review. Clinical Neuropharmacology 1998; 21: 347.
4. Diaz-Marot A, Puigdellivol E, Salvatella C, Comellas L and Gassiot M. Determination of buspirone and 1-(2-pyrimidinyl) piperazine in plasma samples by high-performance liquid Chromatography. Journal of Chromatography B Biomedical Science Applications 1989; 490: 470.
5. Flanagan RG. Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors. Annals of Clinical Biochemistry 1988; 35: 261.
6. Gammans RE, Kerns EH and Bullen WW. Capillary gas chromatographic-mass spectrometric determination of buspirone in plasma. Journal of Chromatography 1985; 345: 285.
7. Goa KL and Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114.
8. Kristjànsson F. Sensitive determination of buspirone in serum by solid-phase extraction and two-dimensional high-performance liquid chromatography. Journal of Chromatography B Biomedical Science Applications 1991; 566: 250.
9. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Annals of Pharmacotherapy 2000; 34: 871.
10. Newton RE, Marunycz JD, Alderdice MT and Napoliello MJ. Review of the side-effect profile of buspirone. American Journal of Medicine 1986; 80: 17.
11. Odontiadis J and Franklin M. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl) piperazine in human plasma by high-performance liquid chromatography with coulometric detection. Journal of Pharmaceutical Biomedical Analysis 1996; 14: 347.
12. Rock NL. Possible adverse effects of buspirone when used with other psychotropic drugs. Journal of Clinical Psychopharmacology 1990; 10: 380.
13. Sciacca MA, Duncan GF, Shea JP, Faulkner HD 3rd, Farmen RH and Pittman KA. Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl) piperazine in human plasma and urine by capillary gas chromatography-mass spectrometry. Journal of Chromatography 1988; 428: 265.